Gooderham, M., Spelman, L., Imafuku, S., Romanelli, M., Merola, J. F., Armstrong, A. W., Colston, E., Banerjee, S., Scharnitz, T., & Blauvelt, A. (2023). Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN The Journal of Cutaneous Medicine, 7(4), s219.